Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

OBJECTIVE: In clinical trials (CTs), the assessment of minimal residual disease (MRD) has proven to have prognostic value for multiple myeloma (MM) patients. Multiparameter flow cytometry (MFC) and next-generation sequencing are currently used in CTs as effective tools for outcome prediction. We hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Riebl, Veronika, Dold, Sandra Maria, Wider, Dagmar, Follo, Marie, Ihorst, Gabriele, Waldschmidt, Johannes M., Jung, Johannes, Rassner, Michael, Greil, Christine, Wäsch, Ralph, Engelhardt, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414971/
https://www.ncbi.nlm.nih.gov/pubmed/34485145
http://dx.doi.org/10.3389/fonc.2021.708231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414971/
https://www.ncbi.nlm.nih.gov/pubmed/34485145
http://dx.doi.org/10.3389/fonc.2021.708231

Ejemplares similares